Welcome to our dedicated page for Instinct Bio Technical Company Holdings news (Ticker: BIOT), a resource for investors and traders seeking the latest updates and insights on Instinct Bio Technical Company Holdings stock.
Biotech Acquisition Co. (BIOT) news centers on its role as a special purpose acquisition company formed to pursue a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. Recurring updates cover shareholder voting matters, extension proposals, trust-account contributions, redemption mechanics, sponsor-related arrangements, and the capital structure of its Class A ordinary shares and warrants.
Company announcements also include SPAC transaction disclosure categories such as registration statements, proxy materials, material agreements, governance matters, and business-combination process updates, with clinical or regulatory topics appearing when tied to potential healthcare-related transaction disclosures.
Instinct Bio (BIOT) issued an operational update on its GENRÊVER CLINIC platform in Indonesia and related cosmetic product collaborations.
The company has secured a 213 m² premises in South Jakarta’s Gandaria district for its first GENRÊVER clinic, with interior construction underway and a targeted opening by the end of December 2026, subject to construction progress, permitting and operational readiness. Preliminary monthly subscription tiers for the Jakarta clinic have been set at US$400, US$1,000 and US$3,000 per customer, with access dependent on membership terms, physician assessment, capacity and regulation.
Instinct Bio and Invitrx have identified an initial GENRÊVER-branded cosmetic product line for potential manufacture in the United States, targeted to commence within 2026. With Parva Candela, two initial cosmetic products for Indonesia under the GENRÊVER and HAKUA brands—a premium UV cream and a moisturizing gel using HA4 low-molecular-weight hyaluronic acid technology—are also targeted to enter production within 2026, subject to development, regulatory and manufacturing conditions.
Instinct Bio (Nasdaq: BIOT) announced a cooperation agreement with Indonesian manufacturer and distributor PT PARVA CANDELA to jointly develop Indonesia’s cosmetics and personal care market under a “Made in Indonesia, Powered by Japanese Formulation Expertise” concept.
The route to market uses PARVA’s affiliation with DELTASPA Group, which operates approximately 25 spa locations across Indonesia, and Instinct Bio’s B2B and B2C sales methods. Manufacturing is planned at PARVA’s BPOM‑recognized, GMP-compliant facility, aligned with Japanese GVP/GQP quality frameworks and Indonesia’s halal requirements. Instinct Bio retains ownership of proprietary ingredients and formulations, granting limited licenses and targeting a 50% profit share plus revenue from ingredient supply, formulation royalties, and brand licensing for its GENRÊVER and HAKUA brands. According to Instinct Bio, this is the third pillar of its organic growth strategy and targets a national beauty and personal care market estimated at US$10.5 billion in 2026, growing about 5.5% annually.
Instinct Bio (NASDAQ: BIOT) plans to launch Indonesia’s first subscription-model beauty clinics under its Japanese brand GENRÊVER CLINIC, targeting recurring membership revenue in the country’s fast-growing medical aesthetics market.
The company plans an initial investment of approximately US$1 million to open five directly operated clinics in Jakarta, Surabaya, Bandung, Medan and Bali, using a standardized, machine-led format for capital-light, disciplined rollout. A flagship Jakarta clinic is expected to validate the model before any wider, self-funded expansion based on clinic cash flows. The business will operate via an Indonesian foreign-investment company (PT PMA), with local physician Dr. Mario Damianus Daniel Hadinoto providing medical oversight and regulatory support. Instinct Bio views the clinics as a second revenue stream and potential distribution channel for products using its proprietary technologies, positioned as a strategic gateway to its core regenerative-medicine, stem-cell and iPS-cell initiatives in Asia.